Tom
I'm going snowboarding Wednesday without a helmet. I 'm hoping to improve at least my perspective on ALLP!
They ought to collaberate with these guys.
Company Press Release
SOURCE: Somanetics Corporation
Somanetics Launches New Model SomaSensor
- Achieves Milestone in its Campaign to Profitability -
TROY, Mich., March 4 /PRNewswire/ -- Somanetics Corporation (Nasdaq: SMTS - news) announced today that it has initiated the market launch of a new model SomaSensor® for use with its INVOS® Cerebral Oximeter monitoring system.
(Photo: newscom.com newscom.com )
''The new disposable sensor will reduce our manufacturing cost by nearly 50 percent,'' said Bruce Barrett, Somanetics' president and chief executive officer. ''This SomaSensor, which replaces the prior model, is designed to enable us to recognize additional cost reductions as volume increases.''
The INVOS Cerebral Oximeter monitoring system is the first and only FDA- cleared and commercially-available monitoring system that provides the medical team with noninvasive and continuous information about changes in regional oxygen saturation of the blood in the brain. Brain injury related to some types of surgery is relatively common, and Somanetics believes many of these injuries may be preventable by using information provided by the INVOS Cerebral Oximeter.
''The Company recently introduced an internal program called the Campaign to Profitability,'' Barrett said. ''The program's purpose is to ensure that our entire team is focused on the goal of transforming our growing revenue into a profitable business. While profitability is not just around the corner, the new SomaSensor represents the achievement of an important milestone relating to one element of the program,'' he said.
Low brain oxygen saturation levels during and after surgery are associated with various brain injuries. Surgeons, anesthesiologists and other medical professionals can use the INVOS Cerebral Oximeter during surgery and in other critical care areas of the hospital, such as recovery rooms and intensive care units, to identify brain oxygen imbalances and take corrective action. Such action can potentially improve patient outcome and reduce the costs of care, including the costs of longer intensive care unit and hospital stays and increased post-surgical ventilator support.
The Company's INVOS technology is based on the physics of optical spectroscopy, the interpretation of the interaction between matter and light. It generates no ionizing radiation and produces no known hazardous effects. Using the SomaSensor, low-intensity visible and near-infrared light is transmitted into the brain, and the scattered light is detected. A computer using the Company's proprietary software analyzes this information and provides a continuous digital and trend display of an index of the oxygen saturation in the blood in the area of the brain being monitored.
Except for historical information contained herein, the matters discussed in this news release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Actual results may differ significantly from results discussed in the forward looking statements. Actual results may be affected by, among other things, risks and uncertainties related to new product development cycles, research and development activities, regulatory approvals of new products, introduction of competitive products by others, third party reimbursement, physician training, and other factors set forth from time to time in Somanetics' Securities and Exchange Commission filings including Somanetics' Registration Statement on Form S-1 (file no. 333-47225) effective April 2, 1998.
Somanetics' Common Shares are traded on the Nasdaq SmallCap Market under the symbol SMTS.
SOURCE: Somanetics Corporation
--------------------------------------------------------------------------------
More Quotes and News: Somanetics Corp (Nasdaq:SMTS - news)
Related News Categories: health care, medical/pharmaceutical
--------------------------------------------------------------------------------
I e-mailed Gwen. " Show us a sign " ...Insider buying would be helpful!
John |
